Bioelectronics Corp (BIEL)

[JustGoDeep]

BUY+++ BIEL MONSTER STOCK COMING +++BUY

Biel: Current Market Cap $18 Million

FDA Clearance
Back Study Complete, results fantastic and the FDA has requested a pre-submission meeting.
Will clear for all muscular/skeletal indications.
Currently in talks with Walmart and CVS
3-5 calls a day with people wanting to partner or distribute

Average user uses 10.8 Actipatches per year, per the U.K. Study.

Keep in mind People Biel

now has Purdue's Mundi Pharmaceuticals on board in 23 Countries,

Teva's ANDA, INC. selling in America, and Patterson Medical's Performance Health

also selling in America.

Anda has 80 Boots on the Ground and 60,000 customers of which 10,000 are pharmacies.

Performance Health has 120 Boots on the Ground and 40 online sales people calling on

all the physical therapy clinics in America, and most of the Long Term Facilities in America.

Using the NHS decision data of saving $582.00 per patient when they use Actipatch,

the Future for Biel has Never been brighter!!

https://www.accessdata.fda.gov/cdrh_docs/pdf15/K152432.pdf

NHS is going to pay starting April 4th by Prescription. 100,000 a day see a doctor for pain.


https://globenewswire.com/news-release/2018/01/04/1283220/0/en/BioElectronics-ActiPatch-Drug-Free-Pain-Therapy-Receives-United-Kingdom-National-Health-System-Payment-Coverage.html

Great Interview with their go to guy for sales and marketing.

https://upticknewswire.com/featured-interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel/

Study NHS made their decision on. 10.8 Actipatches used a year per patient.

www.actipatch.com/actipatch/wp-content/uploads/2014/11/ActiPatch-3-month-Cost-Study-Final.pdf

-----------------------------

The-National-Health-System-has-given-its-approval-to-the ActiPatch, a wearable device that manages peripheral nerve activity to help users suffering from pain. The government-funded health service will now allow UK physicians to prescribe ActiPatch Musculoskeletal Pain Therapy and reimburse them for the digital health offering.

“This is a major win for pain sufferers in the UK, since they will now be able to obtain a prescription for ActiPatch, the cost of which will be covered by the government,” Ian Rawe, PhD, Director of Clinical Research for BioElectronics, the Maryland-based developer of the ActiPatch, said in a press release. “We commend this move by the NHS, as this will open up the doors for reimbursement in the US and other managed care markets.”

UK researchers estimated in 2016 that roughly 43 percent of the nation’s adult population, or about 29 million people, are affected by chronic pain (estimates have placed that figure at 100 million in the US). As in the US and other countries, treatment generally consists of a combination of physical therapy and medication – the likes of which have led to an increase in opioid dependence and abuse.

BioElectronics officials say NHS approval was linked to a study in which treatment with the mHealth wearable helped reducers reduce their trips to the doctor’s office by almost 60 percent and cut prescription drug costs by 35 percent, resulting in an overall reduction in healthcare costs of 45 percent.

------------------------

So much Great News will come out in

the next 6 months that I expect "at least" a 1000% increase.

But let's do some pricing to place a PE value on the Company.

$1,000,000 a quarter in Profit is $4,000,000 (Million) a year.

18 Billion shares outstanding and 20 Billion Authorized. I will use the 20 Billion figure.

$4,000,000 divided by 20 Billion = $.0002 X PE =

PE 30 = $.006

PE 60 = $.012

PE 120 =$.024

High growth companies can sport a much higher PE.

Those numbers are for just $1,000,000 profit in a quarter.

How high will Profit be in Q2, Q3 and Q4.

So by the time this company is making profit of $5 million a quarter or $20 Million a year

and it will, the price per share will be at least PE 60 and at least $.06 per share.

Can it achieve that by Q2, Q3, or after Q4 earnings, I do believe so.

Could it do substantially more? Absolutely. Less, perhaps, but this is going to be huge.

Stock Rating: SUPER MONSTER